Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed COO
Quarterly results
Director departure
Appointed director
|
|
CARACO PHARMACEUTICAL LABORATORIES LTD (CPD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/31/2011 |
8-K
| Form 8-K - Current report |
| 10/29/2010 |
8-K
| Form 8-K - Current report |
| 07/28/2010 |
8-K
| Form 8-K - Current report |
| 01/29/2010 |
8-K
| Form 8-K - Current report |
| 10/27/2009 |
8-K
| Quarterly results|
Docs:
|
"Amendment to Article IV, Section 1 of the Amended and Restated Bylaws of the Company",
"Amendment to Article III, Section 2 of the Amended and Restated Bylaws of the Company",
"CARACO PHARMACEUTICAL LABORATORIES, LTD. STATEMENTS OF INCOME Six Months ended September 30, Quarter ended September 30, 2009 2008 2009 2008 Net sales $ 126,445,911 $ 230,465,165 $ 78,375,895 $ 122,188,425 Cost of goods sold 118,243,578 184,879,891 75,010,528 100,186,562 Gross profit before reserve for inventory seized by FDA 8,202,333 45,585,274 3,365,367 22,001,863 Reserve for inventory seized by FDA 15,950,188 - 7,503,654 - Gross profit 45,585,274 22,001,863 Selling, general and administrative expenses 10,452,575 8,055,246 6,793,364 4,237,244 Research and development costs - other 5,592,951 11,065,940 5,581,711 Operating income prior to non-recurring income 26,464,088 12,182,908 Non-recurring income 20,000,000 - 20,000,000 - Operating income 26,464,088 10,560,533 12,182,908 Other inco..." |
|
| 07/29/2009 |
8-K
| Quarterly results |
| 10/23/2008 |
8-K
| Quarterly results|
Docs:
|
"CARACO PHARMACEUTICAL LABORATORIES, LTD. STATEMENTS OF INCOME Six months ended September 30, Quarter ended September 30, 2008 2007 2008 2007 Net sales $ 230,465,165 $ 76,754,883 $ 122,188,425 $ 41,354,567 Cost of goods sold 184,879,891 42,871,307 100,186,562 23,338,768 Gross profit 45,585,274 33,883,576 22,001,863 18,015,799 Selling, general and administrative expenses 8,055,246 6,436,725 4,237,244 3,034,058 Research and development costs - affiliate — 5,440,000 — 5,440,000 Research and development costs - other 11,065,940 8,389,210 5,581,711 5,103,723 Operating income 26,464,088 13,617,641 12,182,908 4,438,018 Other income Interest income 420,259 886,455 142,486 419,162 Other income 420,259 886,455 142,486 419,162 Net income before income taxes 26,884,347 14,504,096 12,325,394 4,857,180 I..." |
|
| 07/25/2008 |
8-K
| Quarterly results |
| 05/29/2008 |
8-K
| Quarterly results|
Docs:
|
"Caraco Pharmaceutical Laboratories Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 DETROIT, Michigan, May 29, 2008 -- Caraco Pharmaceutical Laboratories, Ltd. posted record net sales for the fourth quarter and the year ended March 31, 2008 , of $191.8 million and $350.4 million, respectively, as compared to $32.7 million and $117.0 million for the corresponding periods of Fiscal 2007. Net income grew to $11.5 million and $35.4 million for the fourth quarter and Fiscal 2008, respectively, as compared to net income of $9.5 million and $26.9 million during the corresponding periods of Fiscal 2007. The annual net income of $35.4 million for Fiscal 2008 was a record for the Company. Daniel H. Movens, Caraco’ s Chief Executive Officer, said, “Our sales results for the fou..." |
|
| 10/24/2007 |
8-K
| Quarterly results |
| 07/24/2007 |
8-K
| Quarterly results|
Docs:
|
"Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the First Quarter Fiscal 2008 DETROIT, Michigan, July 20,2007 -- Caraco Pharmaceutical Laboratories, Ltd. posted record net sales for the first quarter of fiscal 2008, ended June 30, 2007, of $35.4 million, as compared to $24.8 million for the corresponding period of fiscal year 2007. This represents an increase of 43% over the first quarter of fiscal 2007. We earned a net pre-tax income of $9.6 million during the first quarter of fiscal 2008, as compared to a net pre-tax income of $5.0 million during the corresponding period of fiscal 2007. We earned net income of $8.5 million in the first quarter of fiscal 2008 as compared to net income of $5.0 million during the corresponding period of fiscal 2007. Daniel H. Movens, Ca..." |
|
| 01/26/2007 |
8-K
| Quarterly results|
Docs:
|
"Nine Months ended December 31, Quarter ended December 31, 2006 2005 2006 2005 Net sales $ 84,288,303 $ 58,087,910 $ 31,257,187 $ 20,678,978 Cost of goods sold 41,915,021 29,861,857 16,126,034 10,329,598 Gross profit 42,373,282 28,226,053 15,131,153 10,349,380 Selling, general and administrative expenses 7,105,896 5,701,231 2,603,035 2,133,346 Research and development costs - affiliate 11,761,280 21,047,360 — 7,137,280 Research and development costs - other 6,778,204 5,512,554 2,734,727 1,848,167 Operating income 16,727,902 9,793,391 Other income Interest expense — — — Interest income 616,321 108,130 266,074 54,820 Other income 39,897 42,635 6 33,637 Other income 628,024 150,765 266,080 88,457 Net income $ 17,355,926 $ 10,059,471 Net income per common share Basic 0.66 0.38 Diluted 0.45 0.26..." |
|
| 07/26/2006 |
8-K
| Quarterly results|
Docs:
|
"Caraco Pharmaceutical Laboratories Ltd. Reports Solid Sales Growth and Profit for Q1 Fiscal 2007 Net Sales Rise over 40% DETROIT, July 24, 2006 -- Caraco Pharmaceutical Laboratories, Ltd. posted record net sales for Q1 of fiscal 2007, ended June 30, 2006 of $24.8 million as compared to $17.6 million for the corresponding period of fiscal 2006, representing over 40% growth. During Q1 fiscal 2007 net income grew to $5.0 million as compared to $1.6 million in net income for the corresponding period of fiscal 2006. Daniel H. Movens, Caraco's Chief Executive Officer, said “The Company continues to head in the right direction. Considering the previous quarter ended March 31, 2006 included initial sales from our launch of our generic version Ultracet® and we still outperformed that quarter, i..." |
|
| 08/04/2005 |
8-K
| Quarterly results |
| 10/22/2003 |
8-K
| Quarterly results |
| 07/31/2003 |
8-K
| Quarterly results |
|
|